284049-22-5

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, (2-isocyanatoethyl)-, 1,1-dimethylethyl ester (9CI) is used as an active pharmaceutical ingredient for the treatment of various medical conditions, such as cancer, fatty liver, and inflammation. Its isocyanate group enables it to interact with biological targets and modulate their activity, making it a promising candidate for drug development.
Used in Cancer Treatment:
In the field of oncology, Carbamic acid, (2-isocyanatoethyl)-, 1,1-dimethylethyl ester (9CI) is used as a chemotherapeutic agent for the treatment of various types of cancer. Its isocyanate group can potentially react with cellular components, leading to the disruption of cancer cell growth and proliferation.
Used in Treatment of Fatty Liver:
Carbamic acid, (2-isocyanatoethyl)-, 1,1-dimethylethyl ester (9CI) is also used as a therapeutic agent for the treatment of fatty liver disease. Its ability to modulate cellular processes may help in reducing the accumulation of fat in the liver and improving liver function.
Used in Anti-Inflammatory Applications:
In the context of inflammation, Carbamic acid, (2-isocyanatoethyl)-, 1,1-dimethylethyl ester (9CI) is used as an anti-inflammatory agent. Its potential to interact with cellular targets and modulate inflammatory pathways may help in reducing inflammation and alleviating symptoms associated with various inflammatory conditions.

Upstream product

• 39501-21-8 (2-azidocarbonyl-ethyl)-carbamic acid tert-butyl ester 
• 3303-84-2 3-(tert-butyloxycarbonylamino)propionic acid 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 57260-73-8 N-BOC-1,2-diaminoethane 

Downstream Products

• 254100-95-3 O-succinimidyl-2-(tert-butoxycarbonylamino)ethylcarbamate 

Relevant academic research and scientific papers

A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS

Provided is a conjugation of cytotoxic drug to a cell-binding molecule with a side-chain linker. It provides side-chain linkage methods of making a conjugate of a cytotoxic molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and immunological disorders.

Curcumin derivative and uses thereof

The present invention relates to a curcumin derivative represented by a general formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method thereof, a composition containing aneffective amount of the compound represented by the general formula (I) or the pharmaceutically acceptable salt thereof, and applications of the compound represented by the general formula (I) or thepharmaceutically acceptable salt thereof in preparation of drugs for treatment of cancers, fatty liver, inflammations and the like, wherein R and R are defined in the specification.

A nonpeptidic reverse-turn scaffold stabilized by urea-based dual intramolecular hydrogen bonding

A novel nonpeptidic reverse-turn scaffold containing urea fragments that are connected by a conformationally constrained d-prolyl-cis-1,2- diaminocyclohexane (d-Pro-DACH) linker is reported. The scaffold adopts a well-defined reverse-turn conformation tha

IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER

The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N- ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3- trifluoropropylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2- cyanoethylaminomethyl, mopholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1- azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or halo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or a pharmaceutically acceptable salt thereof.